Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 14 2019 - 4:05PM
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage
biopharmaceutical company focused on the development and
commercialization of innovative therapeutics, today announced that
the Company will present at the 8th Annual SVB Leerink Global
Healthcare Conference on Thursday, February 28 at 1:00 p.m. EST at
the Lotte New York Palace in New York.
To access the live webcast of Paratek's presentation, please
visit http://wsw.com/webcast/leerink32/prtk/. Please connect to the
web site at least 15 minutes prior to the live presentation to
ensure adequate time for any software downloads that may be
necessary to listen to the webcast. A replay of the webcast can be
accessed for up to 90 days following the live presentation.
About Paratek Pharmaceuticals, Inc.Paratek
Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapeutics. The company’s lead commercial product,
NUZYRA (omadacycline), is a once-daily intravenous and oral
antibiotic for the treatment of adults with community-acquired
bacterial pneumonia and acute bacterial skin and skin structure
infections. Paratek is also studying NUZYRA for the treatment
of urinary tract infections (UTI). Paratek has
submitted a marketing authorization application of omadacycline in
the European Union. Paratek has entered into a collaboration
agreement with Zai Lab for the development and
commercialization of omadacycline in the greater China region and
retains all remaining global rights. Under a research
agreement with the U.S. Department of Defense, omadacycline also is
being studied against pathogenic agents causing infectious diseases
of public health and biodefense importance, including plague and
anthrax. Paratek’s second FDA-approved product,
SEYSARA™ (sarecycline), is marketed by Almirall, LLC in
the U.S. as a new once-daily oral therapy for the treatment
of moderate to severe acne vulgaris. Paratek
retains development and commercialization rights in the rest
of the world. Recognizing the serious threat of bacterial
infections, Paratek is dedicated to providing solutions
that enable positive outcomes and lead to better patient
stories. For more information,
visit www.ParatekPharma.com or follow
@ParatekPharma on Twitter. Forward Looking
StatementsThis press release contains forward-looking
statements including statements related to our overall strategy,
product candidates, clinical studies, prospects,
potential and expected results, including statements about
the timing of commercialization of NUZYRA, the
potential for omadacycline to serve as an empiric monotherapy
treatment option for patients suffering from ABSSSI, CABP, and
potentially UTI, and other bacterial infections when
resistance is of concern, the prospect of omadacycline providing
broad-spectrum activity, and our ability to make and sell
NUZYRA. All statements, other than statements of historical
facts, included in this press release are forward-looking
statements, and are identified by words such as “advancing,”
“believe,” “expect,” “well positioned,” “look forward,”
“anticipated,” “continued,” and other words and terms of
similar meaning. These forward-looking statements are based upon
our current expectations and involve substantial risks and
uncertainties. We may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Our actual results and the
timing of events could differ materially from those included in
such forward-looking statements as a result of these risks and
uncertainties. These and other risk factors are discussed under
"Risk Factors" and elsewhere in our Annual Report on Form 10-K for
the year ended December 31, 2017, our Form 10-Q filed for the
quarter ended September 30, 2018 and our other filings with
the Securities and Exchange Commission. We expressly disclaim any
obligation or undertaking to update or revise any forward-looking
statements contained herein.
CONTACT: |
|
Investor and
Media Relations: |
Ben Strain |
617-807-6688 |
ir@ParatekPharma.com |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024